Navigation Links
URI research couple's method targets cancerous tumors
Date:10/27/2009

KINGSTON, R.I. -October 27, 2009Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects. The URI couple has attracted more than $6 million in grants in four years. In addition, a number of health care and pharmaceutical companies have expressed interest in their work.

It is possible, says Andreev, that one day their detection method could be used as a universal procedure, similar to mammography or colonoscopies. Their harmless imaging test could locate a problem before the patient ever feels ill.

The key lies in the acidity level of cells. While normal cells maintain a pH of 7.4 with little variation, cancer cells, expend a great deal of energy as they rapidly proliferate, pumping protons outside and creating an extracellular pH level of 5.5 to 6.5. (The lower the number, the higher the acidity.)

While scientists have known about tumor acidity for years, they had not devised a way to target it. Donald Engelman in the molecular biophysics and biochemistry lab at Yale University discovered the peptide that targets acidity, but had not employed it until Reshetnyak joined his lab as a postdoctoral student in 2003. She and Andreev, then a senior scientist at an anticancer drug delivery company, suggested an investigation into the peptide's potential as cancer targeting agents.

In 2004, Reshetnyak and Andreev joined the Physics Department at URI and established a biological and medical physics laboratory. The couple continued their collaboration with Engleman and their investigation of the properties of the peptide, now called the pHLIP peptide. After making some modifications to it, they demonstrated that pHLIP could find a tumor in a mouse and deliver imaging or therapeutic agents specifically to cancer cells. The Yale/URI targeting system has a patent pending in the U.S. and Europe.

The researchers suggest their discovery method could be used to monitor other disease development and treatment. It also could play an important role in the study of arthritis, inflammation, infection, infraction, and stroke since those conditions also produce high acidity.

DELIVERY METHOD

In addition to targeting cancerous tumors, the couple has discovered a novel delivery agent, a molecular nanosyringe, which can deliver and inject diagnostic or therapeutic agents specifically to cancer cells.

"Since we know the mechanism of delivery and translocation, we believe that we are able to tune the nanosyringe properties and engineer a novel class of therapeutic and diagnostic agents," says Reshetnyak.

In a project with the Cancer Center at Rhode Island Hospital, the URI researchers have successfully shown that the peptide can deliver nanogold particles into the cancerous tumor. Once in place, the tiny gold particles can absorb more radiation, providing a more lethal dose to the tumor, but not to surrounding health cells.

"Drs. Reshetnyak and Andreev research offers a potential for a new and more effective approach to the treatment of cancer with radiation, making it highly intriguing and important," said Edward S. Sternick, medical physicist-in-chief, Department of Radiation Oncology, Rhode Island Hospital and professor and vice chair radiation oncology at the Warren Alpert Medical School of Brown University.

"About 1.6 million new cancer patients are diagnosed annually in the U.S." says Sternick noting that the number is expected to grow significantly, reaching 2 million cases per year in the next 10 years, a direct reflection of our aging population. Approximately 50 percent of these cancer patients will receive radiation therapy during the course of their disease.

The URI researchers are collaborating on a $1.5 million National Institutes of Heath/National Cancer Institute grant Jason S. Lewis, chief of radiochemistry service at Memorial Sloan-Kettering Cancer Center in Manhattan, New York. "Their research is innovative and exciting," said Lewis. "It is also timely; the understanding of the tumor microenvironment, and in particular, the pH of a tumor is believed to be important in the metastatic spread of cancer. The technology that the couple has developed could, non-invasively, predict the metastatic potential of cancer as well as or monitoring the effectiveness of potential therapies. Their technology may allow for patient personalized therapies in the future."

Through URI's Department of Physics, Reshetnyak and Andreev are collaborating with Rhode Island Hospital on a proposed 5-year degree program that combines medicine and physics. Students would spend four years in college classes and one year at the hospital.

"The proposed URI/RIH medical physics program now under consideration by URI is the first in New England specifically designed to closely integrate academic and clinical preparation," said Rhode Island Hospital's Sternick, noting that a residency requirement is required before someone is eligible to take the American Board of Radiology national certification examinations. "Because our post-graduate two-year medical physics residency training program will run parallel with the URI medical physics program, URI students will have the opportunity throughout their University experience to gain valuable experiential insights about career opportunities available to and the responsibilities of physicists working in the field of cancer diagnosis and treatment where nationwide demand for well-trained clinical medical physicists far exceeds the available supply." One of Andreev's graduate students, James Segala was accepted into RIH's competitive residency program.

Once certified, graduates of the program could easily find work and high salaries at hospitals where they would calculate radiation prescriptions for radiologists. They could also opt to earn a doctorate to conduct research and teach at the university level. Or they could also go to private industry where their expertise is needed in the development of medical devices.


'/>"/>

Contact: Jan Wenzel
wenzel@advance.uri.edu
401-874-2116
University of Rhode Island
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing ... an exercise invention which aids in proper muscle development. , "The Gym & ... Creative Director of World Patent Marketing. "Globalization has threatened the future growth of ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... consumer insights on healthcare, announced today that it has ... report Cool Vendor in Life Sciences, 2016, ... 15, 2016.  The report focuses on life-science- oriented analytics, ... insight from patients and doctors, confirm medication ingestion, and ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, ... Lifecycle Management Solutions (VLMS) today announced that ... services for sufferers of chronic kidney failure ... to manage their corporate validation process. The ... a software solution to manage their validation ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology: